Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Repros Therapeutics Inc.
The objectives of this study were to evaluate the safety and efficacy of Androxal® administered orally once daily for one year in men with secondary hypogonadism and who had completed ZA-003.
Age
18–68
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Total serum testosterone concentrations \< 300 ng/dL at baseline
You may not be if
Presence or history of prostate cancer
Elevated PSA \> 3.5 ng/mL
Clareo Health | Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism
